Colleges, School and Institutes
Willingness to take PhD students
Douglas Ward’s research applies proteomic approaches to discover biomarkers by analysing carefully collected clinical samples. This work capitalises on the advanced mass spectrometry equipment provided by Birmingham Science City, the large patient base in the West Midlands, and local scientific, clinical, bioinformatic and statistical expertise. Most of his work focuses on identifying novel tumour markers for lung, liver, GI tract and bladder cancers. He also uses proteomics to study α-antitrypsin deficiency and organ transplantation. In addition to biomarker discovery, Dr Ward is also interested in using mass spectrometry to assay biomarkers where immunoassays are not suitable, and in the downstream validation of promising candidates.